You are here: Industry Insights > msd

News List

Lynparza crosses superiority boundary for invasive disease-free survival at interim analysis europeanpharmaceuticalreview
February 19, 2021
The OlympiA trial will conduct its primary analysis early, after the Independent Data Monitoring Committee found it met its primary endpoint in BRCA mutated early breast cancer patients.
Keytruda recommended for routine NHS use in lung cancer pharmatimes
February 05, 2021
MSD’s immunotherapy Keytruda (pembrolizumab) has gained a NICE recommendation for NHS England routine commissioning for the first-line treatment of non-small cell lung cancer (NSCLC).
Keytruda scores new EU approval in colorectal cancer pharmatimes
January 27, 2021
MSD’s immunotherapy Keytruda (pembrolizumab) has been approved in the EU for the first-line treatment of metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal cancer.
US approval for MSD’s heart failure med Verquvo pharmatimes
January 22, 2021
The Food and Drug Administration (FDA) in the US has approved MSD’s (known as Merck in the US and Canada) heart failure treatment Verquvo (vericiguat).
Novel antibiotic Recarbrio has launched in the UK pharmatimes
November 20, 2020
MSD’s novel antibiotic treatment Recarbrio has launched in the UK as concerns grow over the rise of antimicrobial resistance (AMR) globally.
Sanofi teams up with MSD to test new oncology treatment pharmatimes
October 30, 2020
Sanofi has entered an agreement with MSD – known as Merck & Co in the US – to collaborate on a phase II trial evaluating its investigational candidate THOR-707 alongside MSD’s immunotherapy Keytruda.
Lynparza scores long-term benefit data in BRCA-mutated ovarian cancer pharmatimes
September 22, 2020
AstraZeneca and MSD’s (Merck) PARP inhibitor Lynparza has demonstrated long-term progression-free survival (PFS) benefit in BRCA-mutated advanced ovarian cancer.
MSD partners with Seattle Genetics on two new oncology projects pharmatimes
September 16, 2020
MSD, known as Merck in the US and Canada, has announced two new oncology collaborations with biotech company and oncology specialist Seattle Genetics.
Kidney cancer charity slams NICE rejection of Keytruda/Inlyta pharmatimes
August 28, 2020
MSD’s Keytruda (pembrolizumab) in combination with Pfizer's Inlyta (axitinib) has been turned down by NICE as first-line treatment for patients with advanced renal cell carcinoma (RCC).
US rejects MSD/Eisai's Keytruda Lenvima combo pharmatimes
July 10, 2020
MSD and Eisai have received a complete response letter (CRL) from the US Food and Drug Administration rejecting accelerated approval of a combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) for liver cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page